Visiopharm offers EU IVDR-certified tools for breast cancer, including the IHC quantification of Ki-67, estrogen receptor (ER), progesterone receptor (PR), and HER2, as well as the detection of tumors in pan cytokeratin-stained slides, hot spot detection, invasive tumor detection, and metastasis detection [64,65]. Here, ERBB2 is linked to breast carcinoma.